Skip to main content
. 2018 Nov 19;36(1):89–99. doi: 10.1111/pde.13723

Figure 1.

Figure 1

Study design
  • a ET for ATMOS‐1 and ATMOS‐2.
  • bGravimetrically measured.

Patients not continuing in the open‐label extension (ARIDO) had a safety follow‐up at Week 5 via telephone.

ASDD, axillary sweating daily diary; ASDD‐C, ASDD‐Children; ET, end of treatment; GT, topical glycopyrronium tosylate; Wk, week